☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Nonalcoholic Steatohepatitis
Arrowhead Entered into an Exclusive License Agreement with GSK to Develop and Commercialize ARO-HSD for Nonalcoholic Steatohepatit...
November 23, 2021
Merck and Hanmi Collaborate to Develop Efinopegdutide for NASH
August 4, 2020
Boehringer Ingelheim Signs a License Agreement with Yuhan Corporation to Develop Dual Agonist for Nonalcoholic Steatohepatitis
July 2, 2019
Gilead Collaborates with Insitro to Discover and Develop Novel Therapies in Nonalcoholic Steatohepatitis (NASH) for 3yrs.
April 17, 2019
Gilead Reports Results of Selonsertib in P-III STELLAR-4 study for Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis...
February 13, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.